Prostate cancer
Conditions
Interventions
case series:Nil
Sponsors
Department of Urology, Shanghai Changhai Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Male, aged <= 85 years; 2.Patients whose pathological diagnosis is prostate cancer; 3.The pathological stage of the patient after radical resection is greater than or equal to pT3b; 4.The patient's radical prostatectomy showed pathological pTN1 (pathologically confirmed lymph node metastasis); 5.Patients with metastatic prostate cancer (M1) that is clearly diagnosed by preoperative imaging; 6.The pathology of the patient after radical resection shows that the Gleason score is greater than or equal to 8; 7.The patient's expected survival time exceeds 12 months.
Exclusion criteria
Exclusion criteria: 1. Patients who have been diagnosed with any other malignant tumor within the past 5 years; 2. Patients with inoperable advanced metastatic prostate cancer; 3. Patients who have used anticoagulant and antiplatelet aggregation drugs for a long time (the anticoagulant has been stopped for less than 1 week); 4. Organ transplant subjects or previous non-autologous (allogeneic) bone marrow or stem cell transplant populations; 5. Subjects who have undergone blood transfusion 1 month before or during the operation; 6. At the same time suffering from other serious systemic diseases, which the investigator believes may interfere with the treatment, evaluation and compliance of this test, including severe respiratory, circulatory, neurological, mental, digestive, endocrine, immune, urinary and other systems disease; 7. Patients who are participating in other clinical trials, or who have participated in other clinical trials and have been completed for less than one year; 8. Patients who are judged by the investigator to be unsuitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood cfDNA detection;Demographic data (sex, age, etc.), past medical history, family medical history and pathological diagnosis (pathological type, TNM staging);Adverse events;Positive rate of incision margin, no recurrence timeof Biochemistry after operation, urine control afteroperation, recovery rate of sexual function afteroperation, quality of life scale, OS, endocrineadverse reactions;Postoperative follow-up information and imaging examination results; | — |
Countries
China
Contacts
Public ContactRen Shancheng
Department of Urology, Shanghai Changhai Hospital
Outcome results
None listed